1. Home
  2. SCYX vs VBIX Comparison

SCYX vs VBIX Comparison

Compare SCYX & VBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCYX
  • VBIX
  • Stock Information
  • Founded
  • SCYX 1999
  • VBIX N/A
  • Country
  • SCYX United States
  • VBIX Israel
  • Employees
  • SCYX N/A
  • VBIX N/A
  • Industry
  • SCYX Biotechnology: Pharmaceutical Preparations
  • VBIX Computer Software: Prepackaged Software
  • Sector
  • SCYX Health Care
  • VBIX Technology
  • Exchange
  • SCYX Nasdaq
  • VBIX Nasdaq
  • Market Cap
  • SCYX 28.5M
  • VBIX 26.4M
  • IPO Year
  • SCYX 2014
  • VBIX N/A
  • Fundamental
  • Price
  • SCYX $0.71
  • VBIX $4.91
  • Analyst Decision
  • SCYX
  • VBIX
  • Analyst Count
  • SCYX 0
  • VBIX 0
  • Target Price
  • SCYX N/A
  • VBIX N/A
  • AVG Volume (30 Days)
  • SCYX 145.5K
  • VBIX 127.3K
  • Earning Date
  • SCYX 08-07-2025
  • VBIX 08-14-2025
  • Dividend Yield
  • SCYX N/A
  • VBIX N/A
  • EPS Growth
  • SCYX N/A
  • VBIX N/A
  • EPS
  • SCYX N/A
  • VBIX N/A
  • Revenue
  • SCYX $2,630,000.00
  • VBIX $19,672,000.00
  • Revenue This Year
  • SCYX $463.61
  • VBIX N/A
  • Revenue Next Year
  • SCYX $310.80
  • VBIX N/A
  • P/E Ratio
  • SCYX N/A
  • VBIX N/A
  • Revenue Growth
  • SCYX N/A
  • VBIX N/A
  • 52 Week Low
  • SCYX $0.66
  • VBIX $0.18
  • 52 Week High
  • SCYX $2.29
  • VBIX $12.00
  • Technical
  • Relative Strength Index (RSI)
  • SCYX 38.69
  • VBIX N/A
  • Support Level
  • SCYX $0.67
  • VBIX N/A
  • Resistance Level
  • SCYX $0.75
  • VBIX N/A
  • Average True Range (ATR)
  • SCYX 0.04
  • VBIX 0.00
  • MACD
  • SCYX 0.00
  • VBIX 0.00
  • Stochastic Oscillator
  • SCYX 33.06
  • VBIX 0.00

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About VBIX Viewbix Inc. Common Stock

ViewBix Inc operates in the field of digital advertising. Along with its subsidiaries, the company performs two main activities that are reported as separate operating segments: the search segment and the digital content segment. Maximum revenue is generated from the digital content segment, which is engaged in the creation and editing of content, in different languages, for different target audiences, to generate revenues from advertising platforms, including Google, Facebook, Yahoo, and Apple, by utilizing such content to obtain internet user traffic for its customers. The search segment develops various technological software solutions, which perform automation, optimization, and monetization of internet campaigns, to obtain and route internet user traffic to its customers.

Share on Social Networks: